Diopsys, which offers modern visual electrophysiology medical devices, is expected to help create a complementary diagnosis and monitoring platform to LumiThera’s eye care treatment platform Valeda light delivery system
In November last year, LumiThera first signed an agreement to acquire Diopsys. (Credit: Daniel Roberts from Pixabay)
Commercial stage medical device firm LumiThera has wrapped up the acquisition of modern visual electrophysiology medical devices provider Diopsys for an undisclosed sum.
Diopsys’s visual electrophysiology medical devices are designed to support eye care professionals to study the complete pathway for visual and neuro-visual disorders.
In November last year, LumiThera first signed an agreement to acquire Diopsys, which is expected to help create a complementary diagnosis and monitoring platform to the company’s eye care treatment platform Valeda light delivery system.
Valeda light delivery system, which secured CE mark approval, is not yet approved by the US Food and Drug Administration (FDA).
Diopsys offers both visual evoked potential (VEP) and ERG vision testing technology.
The company’s product portfolio consists of Diopsys NOVA, Diopsys ARGOS, and Diopsys RETINA PLUS ERG and VEP vision testing system product series and the Enfant paediatric VEP vision testing system.
Diopsys president Joe Fontanetta said: “The theranostic company will provide the tools eye care professionals need to diagnose, treat, and monitor patients, providing a solution for multiple ocular diseases with limited treatment options.”
LumiThera’s acquisition comes ahead the expected release of its 13-month US LIGHTSITE III trial data in intermediate dry age-related macular degeneration (AMD) patients.
The trial recruited 100 subjects who are given Valeda treatments every four months.
According to the company, a 13-month efficacy timepoint for all patients will offer a predesignated early look at the primary vision endpoint.
Based on the success, the company will further conduct efficacy analysis to support FDA approval.
LumiThera president and CEO Clark Tedford said: “The LIGHTSITE III trial mirrors FDA approval trials for wet AMD drugs in endpoints and duration, in measuring the progression of vision loss in intermediate dry AMD patients, and how Valeda treatments can improve vision and impact disease progression.”
In September 2020, LumiThera partnered with Diopsys to conduct a human clinical trial to treat dry AMD patients.